BidaskClub Lowers BioScrip (NASDAQ:BIOS) to Hold

BidaskClub downgraded shares of BioScrip (NASDAQ:BIOS) from a buy rating to a hold rating in a research note released on Saturday morning, BidAskClub reports.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other brokerages have also recently weighed in on BIOS. SunTrust Banks raised their target price on BioScrip from $3.25 to $4.25 and gave the company a buy rating in a research note on Friday, September 20th. Canaccord Genuity raised their target price on BioScrip from $3.50 to $4.00 and gave the company a buy rating in a research note on Thursday, August 8th. Finally, ValuEngine raised BioScrip from a sell rating to a hold rating in a research note on Wednesday, October 2nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. BioScrip currently has a consensus rating of Buy and a consensus target price of $4.63.

Shares of BIOS stock traded down $0.07 on Friday, hitting $3.59. 894,600 shares of the stock traded hands, compared to its average volume of 1,109,970. The company’s fifty day moving average is $3.46 and its 200 day moving average is $2.81. BioScrip has a 1-year low of $1.56 and a 1-year high of $4.14. The company has a market capitalization of $484.43 million, a PE ratio of -7.33 and a beta of 0.49.

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can bought a new position in BioScrip during the second quarter valued at about $27,000. Jane Street Group LLC bought a new position in BioScrip during the second quarter valued at about $30,000. SG Americas Securities LLC bought a new position in BioScrip during the third quarter valued at about $63,000. North Star Investment Management Corp. purchased a new stake in shares of BioScrip during the third quarter valued at $64,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of BioScrip by 11.2% during the second quarter. JPMorgan Chase & Co. now owns 36,469 shares of the company’s stock valued at $89,000 after purchasing an additional 3,683 shares during the last quarter. 77.46% of the stock is owned by institutional investors and hedge funds.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Featured Article: How do CD ladders protect against rising interest rates?

Analyst Recommendations for BioScrip (NASDAQ:BIOS)

Leave a Reply

Your email address will not be published. Required fields are marked *

*